Boiron (LTS:0DTF) FFO


LTS:0DTF Boiron SA LTS:0DTF
73 GF Score
Price €27.90
GF Value €33.67
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Boiron FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0DTF
73GF Score
Boiron SA LTS:0DTF
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Boiron (LTS:0DTF) Overvalued in 2026?

Based on GuruFocus' analysis, Boiron stock appears to be undervalued. The current stock price of €27.90 is trading 17.1% below its estimated GF Value™ of €33.67. GuruFocus considers Boiron to be Modestly Undervalued.

Key valuation signals for LTS:0DTF:

  • FFO:
  • GF Value™: €33.67 vs. price of €27.90 (17.1% below fair value)
  • GF Score™: 73/100 with 5 warning signs

No single metric tells the full story. See the LTS:0DTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Boiron Business Description

Address 2, Avenue de l’Ouest Lyonnais No. 039, Messimy, FRA, 69510
Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.
73GF Score

Get the complete analysis for LTS:0DTF

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.90
Price
€33.67
GF Value